Treatment of elderly patients with diffuse large B-cell lymphoma

被引：1

作者：

Nösslinger T. ^{[1
]}

机构：

[1] 3rd Medical Department for Hematology and Oncology, Hanusch Krankenhaus, Heinrich Collinstrasse 30, Wien

来源：

memo - Magazine of European Medical Oncology | 2016年 / 9卷 / 1期

关键词：

Comorbidities; Diffuse large B-cell lymphoma; Elderly; R-CHOP; Treatment;

D O I：

10.1007/s12254-016-0248-6

中图分类号：

学科分类号：

摘要：

With the implementation of rituximab, tremendous progress has been achieved in the treatment of diffuse large B-cell lymphoma (DLBCL). Nevertheless, the majority of patients with DLBCL are over the age of 65 years and the management of these patients is often suboptimal. Standard chemo-immunotherapy with curative approach should be appropriate for all elderly patients who can tolerate it. Therefore, a careful evaluation of each patient is mandatory prior to treatment allocation. R- CHOP regimen (rituximab, cyclophosphamide doxorubicin, vincristine, prednisolone) remains the standard of care, but special attention has to be paid to rigorous supportive care. Patients not fit enough for R-CHOP are candidates for dose-reduced therapy or other palliative strategies. © 2016, Springer-Verlag Wien.

引用

页码：8 / 12

页数：4

共 29 条

[1]

Yancik R., Ries L.A., Cancer in older persons: an international issue in an aging world, Semin Oncol, 31, pp. 128-136, (2004)

[2]

Friedberg J.W., Fisher R.I., Diffuse large B-cell lymphoma, Hematol Oncol Clin North Am, 22, pp. 941-952, (2008)

[3]

Ott G., Ziepert M., Klapper W., Et al., Immunoblastic morphology, but not the immune-histochemical GCB/non-GCB classfier, predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial, Blood, 116, 23, pp. 4916-4925, (2010)

[4]

Thunberg U., Enblad G., Berglund M., Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the non-GC subgroup and younger patients in the GC subgroup, Haematologica, 97, 2, (2012)

[5]

A predictive model for aggressive Non-Hodgkin’s Lymphoma, N Engl J Med, 329, pp. 987-994, (1993)

[6]

Zhou Z., Sehn L.H., Rademaker A.W., Et al., An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era, Blood, 123, 6, pp. 837-842, (2014)

[7]

Cheson B.D., Fisher R.I., Barrington S.F., Et al., Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, 32, 27, pp. 3059-3068, (2014)

[8]

Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, 40, pp. 373-383, (1987)

[9]

Linn B.S., Linn M.W., Gurel L., Cumulative illness rating scale, J Am Geriatr Soc, 16, 5, pp. 622-626, (1968)

[10]

Sorror M.L., Sandmaier B.M., Storer B.E., Et al., Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation, J Clin Oncol, 25, 27, pp. 4246-4254, (2007)

← 1 2 3 →